Mitiperstat for COPD
(CRESCENDO Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores the effectiveness of a new drug, Mitiperstat, for individuals with chronic obstructive pulmonary disease (COPD), a condition that makes breathing difficult. Researchers aim to determine if Mitiperstat can reduce symptoms and ensure its safety. Participants will receive either the actual drug or a placebo (a pill with no active medicine) to compare results. The trial seeks individuals with moderate to severe COPD, frequent flare-ups, or a long history of smoking who are already on a stable treatment plan. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group of people.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, it mentions that participants should have a stable regimen of triple or dual therapy for at least 3 months before joining, which suggests you may need to continue your current COPD treatment.
Is there any evidence suggesting that Mitiperstat (AZD4831) is likely to be safe for humans?
Research shows that Mitiperstat (AZD4831) is under testing for safety in treating chronic obstructive pulmonary disease (COPD). Previous studies indicate that Mitiperstat is generally well-tolerated. Most side effects, such as headaches and nausea, were mild to moderate and usually manageable. Serious side effects were rare. As the drug remains under study, further information will enhance understanding of its safety.12345
Why do researchers think this study treatment might be promising for COPD?
Unlike the standard treatments for COPD, which typically involve bronchodilators and corticosteroids, Mitiperstat (AZD4831) works by targeting a different pathway. Researchers are excited about this treatment because it inhibits the enzyme myeloperoxidase, which is thought to reduce inflammation and oxidative stress in the lungs. This novel mechanism could potentially offer improved symptom control and better lung function for patients with COPD, setting it apart from existing options.
What evidence suggests that Mitiperstat might be an effective treatment for COPD?
Research shows that Mitiperstat (AZD4831), which participants in this trial may receive, targets a type of inflammation that significantly affects chronic obstructive pulmonary disease (COPD). This inflammation can lead to more frequent flare-ups and worsen the condition. Early findings suggest that Mitiperstat can reduce this inflammation, potentially decreasing flare-ups and improving symptoms in people with COPD. Previous studies have shown promise in improving breathing symptoms, which is crucial for those with moderate to severe COPD. These initial results offer hope that Mitiperstat could effectively manage COPD symptoms.12345
Are You a Good Fit for This Trial?
Adults aged 40-80 with moderate to severe COPD, who are current or ex-smokers with a significant smoking history. They must have had at least one exacerbation in the past two years or show other signs of high risk for exacerbations and be on a stable regimen of COPD therapy.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Mitiperstat (AZD4831) or placebo for up to 24 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- AZD4831
Find a Clinic Near You
Who Is Running the Clinical Trial?
AstraZeneca
Lead Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology